Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Surgical Science Sweden ABSUSRF 84 Revenue per Share is $2.14 as of Jun. 2026. GuruFocus rates SUSRF with a GF Score™ of 84/100 and a GF Value™ of $19.54 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 610 Healthcare Providers & Services companies, Surgical Science Sweden AB ranks better than 51.64% on this metric.
Surgical Science Sweden AB's revenue per share for the
three
months ended in Jun. 2026 was $0.52.
Surgical Science Sweden AB's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was $2.14.
Warning Sign:
Surgical Science Sweden AB revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of Surgical Science Sweden AB was 8.40% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 7.30% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 38.80% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 28.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Surgical Science Sweden AB's Revenue per Share or its related term are showing as below:
SUSRF'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.2 Med: 19.15 Max: 78.5
Current: 7.3
During the past 11 years, Surgical Science Sweden AB's highest 3-Year average Revenue Per Share Growth Rate was 78.50% per year. The lowest was -1.20% per year. And the median was 19.15% per year.
SUSRF's 3-Year Revenue Growth Rate is ranked better than 51.64% of 610
companies
in the Healthcare Providers & Services industry
Industry Median: 6.95
vs SUSRF: 7.30
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Surgical Science Sweden AB Revenue per Share Related Terms
Surgical Science Sweden AB Revenue per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgical Science Sweden AB Revenue per Share Chart
SUSRF vs VEEV, BTSG, TEM: Revenue per Share Comparison
For the Health Information Services subindustry, Surgical Science Sweden AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgical Science Sweden AB PS Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Surgical Science Sweden AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Surgical Science Sweden AB's PS Ratio falls into.
Surgical Science Sweden AB Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Surgical Science Sweden AB's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.14
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgical Science Sweden AB (SUSRF) has a Revenue per Share of $2.14 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Surgical Science Sweden AB and its competitors. According to the industry distribution chart, Surgical Science Sweden AB ranks #295 out of 610 companies in the Healthcare Providers & Services industry, placing it in the top 48.4%.
Is Surgical Science Sweden AB's Revenue per Share too high?
Surgical Science Sweden AB's current Revenue per Share is $2.14. The Healthcare Providers & Services industry median Revenue per Share is 6.95. Surgical Science Sweden AB's value of $2.14 is 69.2% below this industry median. Based on the distribution chart, Surgical Science Sweden AB ranks #295 out of 610 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Surgical Science Sweden AB has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Surgical Science Sweden AB's Revenue per Share compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Surgical Science Sweden AB ranks #295 out of 610 companies for Revenue per Share. This puts Surgical Science Sweden AB in the upper half of its industry. The industry median Revenue per Share is 6.95. Surgical Science Sweden AB's value of $2.14 is 69.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Healthcare Providers & Services company?
The median Revenue per Share among Healthcare Providers & Services companies is 6.95, based on 610 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surgical Science Sweden AB's current Revenue per Share of $2.14 is 69.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Surgical Science Sweden AB and its competitors. For the Healthcare Providers & Services industry, the median Revenue per Share is 6.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surgical Science Sweden AB's current Revenue per Share is $2.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Science Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Surgical Science Sweden AB (SUSRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $19.54, compared to a current price of $5.20 — trading 73.4% below its estimated fair value. The current Revenue per Share is $2.14 and 69.2% below the Healthcare Providers & Services industry median of 6.95. Surgical Science Sweden AB's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Surgical Science Sweden AB (SUSRF), the current Revenue per Share is $2.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgical Science Sweden AB (SUSRF) Overvalued in 2026?
Based on GuruFocus' analysis, Surgical Science Sweden AB stock appears to be undervalued.
The current stock price of $5.20 is trading 73.4% below its estimated GF Value™ of $19.54.
GuruFocus considers Surgical Science Sweden AB to be Significantly Undervalued.
Key valuation signals for SUSRF:
Revenue per Share: $2.14
GF Value™: $19.54 vs. price of $5.20 (73.4% below fair value)
Industry Position: 69.2% below the Healthcare Providers & Services median (#295 of 610)
No single metric tells the full story. See the SUSRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.
84GF Score
Get the complete analysis for SUSRF
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SUSRF has been successfully added to your 
